Bell Potter Healthcare Conference 2020 Live-stream
8:00AM
WELCOME
James Unger, Head of Corporate Finance
MID CAP PHARMA
8:05AM
EXPERIENCE ON COVID-19 TO DATE
Mesoblast (MSB)
Silviu Itescu, Chief Executive Officer
Dr Fred Grossman, Chief Medical Officer
8:30AM
WET AGE-RELATED MACULAR DEGENERATION – WHAT’S IN THE PIPELINE?
Opthea (OPT)
Megan Baldwin, Managing Director & Chief Executive Officer
8:55AM
ZILUSOL COMMERCIALISATION UPDATE
Paradigm Biopharmaceuticals (PAR)
Paul Rennie, Chief Executive Officer
MID CAP HEALTHCARE
9:20AM
LOCAL AND GLOBAL EXPANSION PLANS
AFT Pharmaceuticals (AFP)
Hartley Atkinson, Chief Executive Officer
Malcolm Tubby, Chief Financial Officer
9:45AM
DELIVERING IMPROVED OUTCOMES – FOR COVID-19 AND BEYOND
Starpharma Holdings (SPL)
Jackie Fairley
Chief Executive Officer
10:10AM
EMVISION’S PILOT CLINICAL TRIAL FOR ITS BREAKTHROUGH PORTABLE BRAIN SCANNER
EMvision Medical Devices (EMV)
Dr Ron Weinberger, Managing Director
Scott Kirkland, Executive Director
COVID-19
10:45AM
THE GLOBAL IMPACT OF COVID-19 ON TELEHEALTH AND MENTAL HEALTH
Doctor Care Anywhere (DOC)
Bayju Thakar, Chief Executive Officer
Kate Bunyan, Chief Medical Officer
Total Brain (TTB)
Louis Gagnon, Chief Executive Officer & Managing Director
11:15AM
THE IMPACT OF COVID-19 ON THE HOSPITAL SYSTEM
Oneview Healthcare (ONE)
James Fitter, Chief Executive Officer
Royal Rehabilitation Group
Matthew MacKay, Chief Executive Officer
PainChek (PCK)
Philip Daffas, Chief Executive Officer
John Murray, Non-Executive Director
11:45AM
HUNT FOR THE COVID-19 VACCINE
Bioshares
David Blake, Editor/Analyst & Co-founder of Bioshares
12:15PM
AUSTRALIA’S PUBLIC HEALTH RESPONSE TO THE COVID-19 PANDEMIC, PRE AND POST VACCINE IMPLEMENTATION
Dr. Rob Grenfell, Director CSIRO Health & Biosecurity
Professor Jodie McVernon, Professor and Director of Epidemiology
WOUND
12:40PM
1Q21 COMPANY UPDATE
Avita Therapeutics (AVH)
Mike Perry, Chief Executive Officer
1:05PM
BEYOND JUST BURNS – A VIRTUAL TOUR OF THE NEW PRODUCT MANUFACTURING FACILITY
Polynovo (PNV)
Paul Brennan, Chief Executive Officer
Jan-Marcel Gielen, Chief Financial Officer
1:30PM
CELGRO: RETURNING FUNCTION TO PARALYSED LIMBS
Orthocell (OCC)
Paul Anderson, Managing Director & Chief Executive Officer
1:55PM
A DEEP DIVE INTO THE BATTLE AGAINST BIOFILM
Next Science (NXS)
Judith Mitchell, Managing Director
Dr. Thorsten M. Seyler, MD & PhD
2:20PM
CLINICAL UPDATES AND INSIGHTS: A DISCUSSION WITH TELA BIO’S CHIEF MEDICAL OFFICER
Aroa Biosurgery (ARX)
Brian Ward, Chief Executive Officer
Dr Maarten Persanaire, TELA Bio’s Chief Medical Officer
2:50PM
PANEL DISCUSSION: TRENDS IN ADVANCED WOUND CARE
Aroa Biosurgery (ARX)
Brian Ward, Chief Executive Officer
James Agnew, Chief Financial Officer
Polynovo (PNV)
Paul Brennan, Chief Executive Officer
Jan-Marcel Gielen, Chief Financial Officer
3:50PM
WRAP UP
James Unger, Head of Corporate Finance
Day 2 Schedule: Thursday, 26 November 2020
8:00AM
WELCOME
Anton Whitehead, Director of Equity Capital Markets
IMAGING SOFTWARE
8:05AM
VISAGE AI ACCELERATOR- A PLATFORM APPROACH TO AI IN RADIOLOGY
Pro Medicus (PME)
Dr Sam Hupert, Chief Executive Officer
8:30AM
RESILIENCE AND CASE STUDIES
Volpara Heatlh Technologies (VHT)
Ralph Highnam, Chief Executive Officer
8:55AM
COMMERCIALISATION OF XV TECHNOLOGY
4D Medical (4DX)
Andreas Fouras, Chief Executive Officer
9:20AM
COMMERICALISATION UPDATE
Mach 7 Technologies (M7T)
Mike Lampron, Chief Executive Officer
Jenni Pilcher, Chief Financial Officer
SMALL CAP PHARMACEUTICALS/ DIAGNOSTICS
9:55AM
DEPTH IN PRODUCTS AND PHARMA PARTNERSHIPS
Immutep (IMM)
Marc Voigt, Chief Executive Officer
10:15AM
UPDATE FROM GENETIC SIGNATURES SALES DIRECTORS
Genetic Signatures (GSS)
John Melki, Chief Executive Officer
Jackson Jones, Director of Global Sales and Marketing
10:35AM
LIVE DEMO OF EASY TO USE, AWARD WINNING RAPID TESTS FOR COVID-19 AND OTHERS
Atomo Diagnostics (AT1)
John Kelly, Chief Executive Officer
Will Souter, Chief Financial Officer
10:55AM
US COMMERICALISATION UPDATE
Cyclopharm (CYC)
James McBrayer, Chief Executive Officer
ONCOLOGY AND IMMUNO ONCOLOGY
11:35AM
COMMERICALISATION UPDATE
Oncosil Medical (OSL)
Daniel Kenny, Chief Executive Officer
11:55AM
TRANSITIONING TO A PIVOTAL STUDY
Kazia Therapeutics (KZA)
James Garner, Chief Executive Officer
12:15PM
IDIOPATHIC INTRACRANIAL HYPERTENSION (IIH) – A CLINICIAN’S PERSPECTIVE ON THIS RAPIDLY GROWING AND COSTLY DISORDER
Invex Therapeutics (IXC)
Tom Duthy, Executive Director
MID CAP DEVICES
12:55PM
PENTHROX: UNLOCKING OUR POTENTIAL IN EUROPE
Medical Developments International (MVP)
Brent MacGregor, Chief Executive Officer
1:20PM
BUSINESS UPDATE
Nanosonics (NAN)
Michael Kavanagh, Chief Executive Officer
McGregor Grant, Chief Financial Officer
1:45PM
PROCEDURE DEMONSTRATION OF IMRICOR’S NOVEL MRI COMPATIBLE CATHETERS
Imricor Medical Systems (IMR)
Steve Wedan, Chief Executive Officer
2:10PM
FOCUS ON ONGOING SALES PROGRESS AND DEMAND, IMPACT OF NEW FACILITY AND CLARITY ON GUIDANCE
Cleanspace (CSX)
Dr Alex Birrell, Chief Executive Officer
Elizabeth Harvey, Chief Financial Officer
2:35PM
TARGETING RADIOPHARMACEUTICALS: FOCUS ON TELIX’S THERAPEUTIC PROGRESS
Telix Pharmaceuticals (TLX)
Dr. Christian Behrenbruch, Chief Executive Officer
Dr. David Cade, Chief Business Officer
3:00PM
WRAP UP
James Unger, Head of Corporate Finance
For more information about the Bell Potter Healthcare Conference, go to our dedicated web page www.bellpotter.com.au/healthcare-conference-2020/